Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 6:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: lorcaserin Clear all
Completed Phase 2 Interventional Results available

Combination Nicotine Patch / Lorcaserin for Smoking Cessation

NCT02906644
View directory record Official record
Conditions
Nicotine Dependence
Interventions
lorcaserin, nicotine patch, placebo lorcaserin
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Sep 21, 2026, 6:11 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Mechanisms of Lorcaserin for Smoking Cessation

NCT04396834
View directory record Official record
Conditions
Tobacco Use Disorder, Smoking Cessation
Interventions
Lorcaserin Oral Tablet, Placebo oral tablet
Drug
Lead sponsor
The Mind Research Network
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 19, 2023 · Synced Sep 21, 2026, 6:11 PM EDT
Completed Phase 3 Interventional Results available

BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus

NCT00603291
View directory record Official record
Conditions
Obesity
Interventions
Lorcaserin 10 mg once daily (QD), Lorcaserin 10 mg twice a day (BID), Matching Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Sep 21, 2026, 6:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose Study to Determine the Safety, Tolerability, and Pharmacokinetic Properties of Lorcaserin Hydrochloride (BELVIQ) in Obese Adolescents From 12 to 17 Years of Age

NCT02022956
View directory record Official record
Conditions
Pharmacokinetics in Obese Adolescents
Interventions
Lorcaserin
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2013
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Sep 21, 2026, 6:11 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Laboratory Screening of Lorcaserin for Alcohol Use Disorder

NCT04396847
View directory record Official record
Conditions
Alcohol Use Disorder, Tobacco Smoking
Interventions
Lorcaserin Oral Tablet, Placebo oral tablet
Drug
Lead sponsor
The Mind Research Network
Other
Eligibility
21 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Sep 6, 2022 · Synced Sep 21, 2026, 6:11 PM EDT
Completed Phase 3 Interventional Results available

BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management

NCT00395135
View directory record Official record
Conditions
Obesity
Interventions
Lorcaserin 10 mg BID, Matching Placebo BID
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
3,182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Sep 21, 2026, 6:11 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Lorcaserin in the Treatment of Cocaine Use Disorder

NCT03007394
View directory record Official record
Conditions
Cocaine-Related Disorders
Interventions
Lorcaserin, Placebo Oral Capsule
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
272 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
12
States / cities
La Jolla, California • Los Angeles, California • Newport Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Sep 21, 2026, 6:11 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Lorcaserin in Obesity: Identification of CNS Targets Using fMRI

NCT02400359
View directory record Official record
Conditions
Obesity, Weight Loss
Interventions
Lorcaserin HCl, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 21, 2026, 6:11 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Lorcaserin for Preventing Weight Gain Among Smokers

NCT02393547
View directory record Official record
Conditions
Tobacco Use Disorder, Weight Gain
Interventions
Varenicline, Lorcaserin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Sep 21, 2026, 6:11 PM EDT
Terminated Phase 1 Interventional

Gene-by-Stress Interactions in Intervention Studies Significance

NCT03011645
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Ziprasidone, Lorcaserin, Placebo Oral Tablet
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 16, 2020 · Synced Sep 21, 2026, 6:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Demonstrate Bioequivalence Between Lorcaserin Extended Release (XR) Tablets Manufactured in Kawashima and Lorcaserin XR Tablets Manufactured in Zofingen in Healthy Participants

NCT03627936
View directory record Official record
Conditions
Healthy Participants
Interventions
Lorcaserin manufactured at Zofingen, Lorcaserin manufactured at Kawashima
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Sep 21, 2026, 6:11 PM EDT
Not listed Phase 2 Interventional

Comparing Lorcaserin Versus Duloxetine for the Treatment of Chemotherapy-Induced Peripheral Neuropathy

NCT03812523
View directory record Official record
Conditions
Chemotherapy-Induced Peripheral Neuropathy
Interventions
Duloxetine 60 mg qd, Lorcaserin
Drug
Lead sponsor
Southeastern Regional Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Newnan, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Sep 21, 2026, 6:11 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome

NCT04572243
View directory record Official record
Conditions
Epilepsies, Myoclonic
Interventions
Placebo, Lorcaserin
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
2 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
25
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Sep 21, 2026, 6:11 PM EDT
Completed Phase 4 Interventional Results available

Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity

NCT03799198
View directory record Official record
Conditions
Obesity
Interventions
Weight Management Program (WMP), Medication for chronic weight management (Rx)
Other · Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 13, 2022 · Synced Sep 21, 2026, 6:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess Potential Interactions Between Intravenous Cocaine and Oral Lorcaserin

NCT02393599
View directory record Official record
Conditions
Cocaine Abuse
Interventions
Lorcaserin, Placebo, Cocaine Infusion
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Sep 21, 2026, 6:11 PM EDT
Completed Phase 1 Interventional Results available

Drug Interaction and Self Administration Studies of Compounds for Cocaine Use Disorder

NCT02537873
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
Lorcaserin, Cocaine Intravenous (IV), Placebo comparator
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 59 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Sep 21, 2026, 6:11 PM EDT
Completed Phase 1 Interventional

To Assess the Effect of Lorcaserin Hydrochloride on Energy Metabolism and Food Intake

NCT00829140
View directory record Official record
Conditions
Obesity
Interventions
Placebo, Lorcaserin 10mg BID
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Sep 21, 2026, 6:11 PM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Lorcaserin Intra Venous Cocaine Effects

NCT02680288
View directory record Official record
Conditions
Cocaine Use Disorders
Interventions
Lorcaserin, 10 mg, Lorcaserin, 20 mg, Oral Placebo
Drug · Other
Lead sponsor
Midwest Biomedical Research
Other
Eligibility
21 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Sep 21, 2026, 6:11 PM EDT
Completed Phase 1 Interventional

Pharmacokinetic Properties of Lorcaserin in Obese or Overweight Elderly Subjects

NCT00828581
View directory record Official record
Conditions
Obesity
Interventions
lorcaserin
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Willingboro, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Sep 21, 2026, 6:11 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Predictors of Lorcaserin-Induced Weight Loss

NCT03353220
View directory record Official record
Conditions
Overweight and Obesity
Interventions
Belviq, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Sep 21, 2026, 6:11 PM EDT
Not listed Phase 4 Interventional

Lorcaserin for Weight Loss Management in Patients on Antipsychotics: A Pilot Study

NCT01962402
View directory record Official record
Conditions
Weight Gain
Interventions
lorcaserin, Intensive dietary counseling
Drug · Behavioral
Lead sponsor
Southern California Institute for Research and Education
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2014 · Synced Sep 21, 2026, 6:11 PM EDT
Completed Phase 4 Interventional Results available

A Multicenter, Double-blind, Randomized, Parallel-group, Pilot Study of 12-week Duration to Assess the Short-term Safety and Tolerability of Lorcaserin Plus Two Doses of Immediate-Release Phentermine-HCl Compared With Lorcaserin Alone in Overweight and Obese Adults

NCT01987427
View directory record Official record
Conditions
Chronic Weight Management
Interventions
lorcaserin + phentermine placebo, lorcaserin + phentermine-HCl + phentermine placebo, lorcaserin + phentermine-HCl
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
13
States / cities
Birmingham, Alabama • Chandler, Arizona • La Jolla, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2019 · Synced Sep 21, 2026, 6:11 PM EDT
Completed Phase 1 Interventional Results available

Drug Interaction and Subjective Effects of Compounds for Opioid Use Disorder

NCT03143855
View directory record Official record
Conditions
Opioid Abuse, Opioid Dependence, Opioid-Related Disorders, Opioid Use
Interventions
Lorcaserin, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 11, 2020 · Synced Sep 21, 2026, 6:11 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Lorcaserin: Real World Experience in an Insurance-Based Weight Management Clinic

NCT03552107
View directory record Official record
Conditions
Obesity, Weight Loss, Overweight
Interventions
Lorcaserin
Drug
Lead sponsor
Scripps Whittier Diabetes Institute
Other
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2019 · Synced Sep 21, 2026, 6:11 PM EDT